nodes	percent_of_prediction	percent_of_DWPC	metapath
Etoricoxib—PTGS2—colon cancer	0.536	1	CbGaD
Etoricoxib—CYP2C9—Capecitabine—colon cancer	0.0379	0.342	CbGbCtD
Etoricoxib—CYP1A2—Fluorouracil—colon cancer	0.0249	0.225	CbGbCtD
Etoricoxib—CYP2C9—Fluorouracil—colon cancer	0.0225	0.203	CbGbCtD
Etoricoxib—CYP3A4—Irinotecan—colon cancer	0.0136	0.123	CbGbCtD
Etoricoxib—CYP3A4—Vincristine—colon cancer	0.0119	0.107	CbGbCtD
Etoricoxib—Vemurafenib—BRAF—colon cancer	0.00766	0.819	CrCbGaD
Etoricoxib—MAPK14—blood vessel—colon cancer	0.00587	0.112	CbGeAlD
Etoricoxib—MAPK14—embryo—colon cancer	0.0035	0.0669	CbGeAlD
Etoricoxib—MAPK14—epithelium—colon cancer	0.00286	0.0546	CbGeAlD
Etoricoxib—MAPK14—smooth muscle tissue—colon cancer	0.00275	0.0526	CbGeAlD
Etoricoxib—MAPK14—renal system—colon cancer	0.00265	0.0507	CbGeAlD
Etoricoxib—MAPK14—lymphoid tissue—colon cancer	0.0022	0.0421	CbGeAlD
Etoricoxib—MAPK14—digestive system—colon cancer	0.00217	0.0415	CbGeAlD
Etoricoxib—MAPK14—bone marrow—colon cancer	0.002	0.0383	CbGeAlD
Etoricoxib—MAPK14—vagina—colon cancer	0.00192	0.0367	CbGeAlD
Etoricoxib—PTGS2—endothelium—colon cancer	0.00183	0.035	CbGeAlD
Etoricoxib—PTGS2—blood vessel—colon cancer	0.00169	0.0323	CbGeAlD
Etoricoxib—MAPK14—liver—colon cancer	0.00162	0.031	CbGeAlD
Etoricoxib—PTGS2—gall bladder—colon cancer	0.00159	0.0304	CbGeAlD
Etoricoxib—MAPK14—lymph node—colon cancer	0.00124	0.0237	CbGeAlD
Etoricoxib—PTGS2—embryo—colon cancer	0.00101	0.0192	CbGeAlD
Etoricoxib—Celecoxib—PTGS2—colon cancer	0.000979	0.105	CrCbGaD
Etoricoxib—CYP2C19—digestive system—colon cancer	0.000924	0.0177	CbGeAlD
Etoricoxib—CYP1A2—renal system—colon cancer	0.00092	0.0176	CbGeAlD
Etoricoxib—CYP2E1—renal system—colon cancer	0.000827	0.0158	CbGeAlD
Etoricoxib—PTGS2—epithelium—colon cancer	0.000821	0.0157	CbGeAlD
Etoricoxib—CYP2C19—vagina—colon cancer	0.000816	0.0156	CbGeAlD
Etoricoxib—PTGS2—smooth muscle tissue—colon cancer	0.000791	0.0151	CbGeAlD
Etoricoxib—PTGS2—renal system—colon cancer	0.000762	0.0146	CbGeAlD
Etoricoxib—CYP1A2—digestive system—colon cancer	0.000754	0.0144	CbGeAlD
Etoricoxib—CYP2C9—digestive system—colon cancer	0.000716	0.0137	CbGeAlD
Etoricoxib—Vismodegib—ABCB1—colon cancer	0.000713	0.0763	CrCbGaD
Etoricoxib—CYP2C19—liver—colon cancer	0.000688	0.0132	CbGeAlD
Etoricoxib—CYP2E1—lymphoid tissue—colon cancer	0.000687	0.0131	CbGeAlD
Etoricoxib—CYP2E1—digestive system—colon cancer	0.000679	0.013	CbGeAlD
Etoricoxib—CYP3A4—renal system—colon cancer	0.000666	0.0127	CbGeAlD
Etoricoxib—CYP2D6—renal system—colon cancer	0.000655	0.0125	CbGeAlD
Etoricoxib—PTGS2—lymphoid tissue—colon cancer	0.000633	0.0121	CbGeAlD
Etoricoxib—PTGS2—digestive system—colon cancer	0.000625	0.0119	CbGeAlD
Etoricoxib—PTGS2—bone marrow—colon cancer	0.000576	0.011	CbGeAlD
Etoricoxib—CYP1A2—liver—colon cancer	0.000562	0.0107	CbGeAlD
Etoricoxib—PTGS2—vagina—colon cancer	0.000552	0.0106	CbGeAlD
Etoricoxib—CYP3A4—digestive system—colon cancer	0.000546	0.0104	CbGeAlD
Etoricoxib—CYP2D6—digestive system—colon cancer	0.000537	0.0103	CbGeAlD
Etoricoxib—CYP2C9—liver—colon cancer	0.000533	0.0102	CbGeAlD
Etoricoxib—CYP2E1—liver—colon cancer	0.000506	0.00967	CbGeAlD
Etoricoxib—PTGS2—liver—colon cancer	0.000466	0.0089	CbGeAlD
Etoricoxib—CYP3A4—liver—colon cancer	0.000407	0.00778	CbGeAlD
Etoricoxib—CYP2D6—liver—colon cancer	0.0004	0.00765	CbGeAlD
Etoricoxib—Anaemia—Irinotecan—colon cancer	0.000362	0.00203	CcSEcCtD
Etoricoxib—Bronchitis—Capecitabine—colon cancer	0.000362	0.00203	CcSEcCtD
Etoricoxib—Abdominal discomfort—Capecitabine—colon cancer	0.000361	0.00202	CcSEcCtD
Etoricoxib—Hepatic failure—Methotrexate—colon cancer	0.000361	0.00202	CcSEcCtD
Etoricoxib—PTGS2—lymph node—colon cancer	0.000357	0.00682	CbGeAlD
Etoricoxib—Vision blurred—Fluorouracil—colon cancer	0.000354	0.00198	CcSEcCtD
Etoricoxib—Upper respiratory tract infection—Capecitabine—colon cancer	0.00035	0.00196	CcSEcCtD
Etoricoxib—Hypertension—Vincristine—colon cancer	0.000348	0.00194	CcSEcCtD
Etoricoxib—Anaemia—Fluorouracil—colon cancer	0.000347	0.00194	CcSEcCtD
Etoricoxib—Photosensitivity reaction—Capecitabine—colon cancer	0.000344	0.00192	CcSEcCtD
Etoricoxib—Weight increased—Capecitabine—colon cancer	0.000343	0.00192	CcSEcCtD
Etoricoxib—Visual disturbance—Methotrexate—colon cancer	0.000342	0.00191	CcSEcCtD
Etoricoxib—Cough—Irinotecan—colon cancer	0.000342	0.00191	CcSEcCtD
Etoricoxib—Hyperglycaemia—Capecitabine—colon cancer	0.00034	0.0019	CcSEcCtD
Etoricoxib—Hypertension—Irinotecan—colon cancer	0.000339	0.00189	CcSEcCtD
Etoricoxib—Pneumonia—Capecitabine—colon cancer	0.000338	0.00189	CcSEcCtD
Etoricoxib—Infestation NOS—Capecitabine—colon cancer	0.000336	0.00188	CcSEcCtD
Etoricoxib—Infestation—Capecitabine—colon cancer	0.000336	0.00188	CcSEcCtD
Etoricoxib—Anaphylactoid reaction—Methotrexate—colon cancer	0.000335	0.00187	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Capecitabine—colon cancer	0.000333	0.00186	CcSEcCtD
Etoricoxib—Acute coronary syndrome—Capecitabine—colon cancer	0.000331	0.00185	CcSEcCtD
Etoricoxib—Cerebrovascular accident—Methotrexate—colon cancer	0.000331	0.00185	CcSEcCtD
Etoricoxib—Renal failure—Capecitabine—colon cancer	0.00033	0.00185	CcSEcCtD
Etoricoxib—Neuropathy peripheral—Capecitabine—colon cancer	0.000329	0.00184	CcSEcCtD
Etoricoxib—Myocardial infarction—Capecitabine—colon cancer	0.000329	0.00184	CcSEcCtD
Etoricoxib—Anaphylactic shock—Vincristine—colon cancer	0.000329	0.00184	CcSEcCtD
Etoricoxib—Oedema—Vincristine—colon cancer	0.000329	0.00184	CcSEcCtD
Etoricoxib—Stomatitis—Capecitabine—colon cancer	0.000327	0.00183	CcSEcCtD
Etoricoxib—Jaundice—Capecitabine—colon cancer	0.000327	0.00183	CcSEcCtD
Etoricoxib—Infection—Vincristine—colon cancer	0.000326	0.00183	CcSEcCtD
Etoricoxib—Conjunctivitis—Capecitabine—colon cancer	0.000326	0.00183	CcSEcCtD
Etoricoxib—Urinary tract infection—Capecitabine—colon cancer	0.000326	0.00183	CcSEcCtD
Etoricoxib—Confusional state—Irinotecan—colon cancer	0.000323	0.0018	CcSEcCtD
Etoricoxib—Nervous system disorder—Vincristine—colon cancer	0.000322	0.0018	CcSEcCtD
Etoricoxib—Thrombocytopenia—Vincristine—colon cancer	0.000322	0.0018	CcSEcCtD
Etoricoxib—Haematuria—Capecitabine—colon cancer	0.00032	0.00179	CcSEcCtD
Etoricoxib—Anaphylactic shock—Irinotecan—colon cancer	0.00032	0.00179	CcSEcCtD
Etoricoxib—Oedema—Irinotecan—colon cancer	0.00032	0.00179	CcSEcCtD
Etoricoxib—Chest pain—Fluorouracil—colon cancer	0.00032	0.00179	CcSEcCtD
Etoricoxib—Infection—Irinotecan—colon cancer	0.000318	0.00178	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Capecitabine—colon cancer	0.000318	0.00178	CcSEcCtD
Etoricoxib—Epistaxis—Capecitabine—colon cancer	0.000317	0.00177	CcSEcCtD
Etoricoxib—Shock—Irinotecan—colon cancer	0.000315	0.00176	CcSEcCtD
Etoricoxib—Nervous system disorder—Irinotecan—colon cancer	0.000314	0.00176	CcSEcCtD
Etoricoxib—Thrombocytopenia—Irinotecan—colon cancer	0.000313	0.00175	CcSEcCtD
Etoricoxib—Anorexia—Vincristine—colon cancer	0.000313	0.00175	CcSEcCtD
Etoricoxib—Confusional state—Fluorouracil—colon cancer	0.000309	0.00173	CcSEcCtD
Etoricoxib—Anaphylactic shock—Fluorouracil—colon cancer	0.000307	0.00171	CcSEcCtD
Etoricoxib—Oedema—Fluorouracil—colon cancer	0.000307	0.00171	CcSEcCtD
Etoricoxib—Anorexia—Irinotecan—colon cancer	0.000305	0.00171	CcSEcCtD
Etoricoxib—Infection—Fluorouracil—colon cancer	0.000305	0.0017	CcSEcCtD
Etoricoxib—Haemoglobin—Capecitabine—colon cancer	0.000303	0.00169	CcSEcCtD
Etoricoxib—Hepatitis—Capecitabine—colon cancer	0.000301	0.00169	CcSEcCtD
Etoricoxib—Haemorrhage—Capecitabine—colon cancer	0.000301	0.00169	CcSEcCtD
Etoricoxib—Nervous system disorder—Fluorouracil—colon cancer	0.000301	0.00168	CcSEcCtD
Etoricoxib—Thrombocytopenia—Fluorouracil—colon cancer	0.0003	0.00168	CcSEcCtD
Etoricoxib—Hypoaesthesia—Capecitabine—colon cancer	0.0003	0.00168	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Vincristine—colon cancer	0.000299	0.00167	CcSEcCtD
Etoricoxib—Pharyngitis—Capecitabine—colon cancer	0.000299	0.00167	CcSEcCtD
Etoricoxib—Urinary tract disorder—Capecitabine—colon cancer	0.000298	0.00167	CcSEcCtD
Etoricoxib—Insomnia—Vincristine—colon cancer	0.000297	0.00166	CcSEcCtD
Etoricoxib—Oedema peripheral—Capecitabine—colon cancer	0.000297	0.00166	CcSEcCtD
Etoricoxib—Connective tissue disorder—Capecitabine—colon cancer	0.000296	0.00166	CcSEcCtD
Etoricoxib—Urethral disorder—Capecitabine—colon cancer	0.000296	0.00165	CcSEcCtD
Etoricoxib—Breast disorder—Methotrexate—colon cancer	0.000293	0.00164	CcSEcCtD
Etoricoxib—Anorexia—Fluorouracil—colon cancer	0.000292	0.00163	CcSEcCtD
Etoricoxib—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.000292	0.00163	CcSEcCtD
Etoricoxib—Visual impairment—Capecitabine—colon cancer	0.000291	0.00162	CcSEcCtD
Etoricoxib—Insomnia—Irinotecan—colon cancer	0.000289	0.00162	CcSEcCtD
Etoricoxib—Decreased appetite—Vincristine—colon cancer	0.000286	0.0016	CcSEcCtD
Etoricoxib—Dyspnoea—Irinotecan—colon cancer	0.000285	0.0016	CcSEcCtD
Etoricoxib—Erythema multiforme—Capecitabine—colon cancer	0.000285	0.00159	CcSEcCtD
Etoricoxib—Somnolence—Irinotecan—colon cancer	0.000285	0.00159	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Vincristine—colon cancer	0.000284	0.00159	CcSEcCtD
Etoricoxib—Fatigue—Vincristine—colon cancer	0.000283	0.00158	CcSEcCtD
Etoricoxib—Eye disorder—Capecitabine—colon cancer	0.000282	0.00158	CcSEcCtD
Etoricoxib—Dyspepsia—Irinotecan—colon cancer	0.000282	0.00158	CcSEcCtD
Etoricoxib—Tinnitus—Capecitabine—colon cancer	0.000281	0.00157	CcSEcCtD
Etoricoxib—Pain—Vincristine—colon cancer	0.000281	0.00157	CcSEcCtD
Etoricoxib—Constipation—Vincristine—colon cancer	0.000281	0.00157	CcSEcCtD
Etoricoxib—Flushing—Capecitabine—colon cancer	0.00028	0.00156	CcSEcCtD
Etoricoxib—Cardiac disorder—Capecitabine—colon cancer	0.00028	0.00156	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000279	0.00156	CcSEcCtD
Etoricoxib—Decreased appetite—Irinotecan—colon cancer	0.000278	0.00156	CcSEcCtD
Etoricoxib—Insomnia—Fluorouracil—colon cancer	0.000277	0.00155	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Irinotecan—colon cancer	0.000276	0.00155	CcSEcCtD
Etoricoxib—Fatigue—Irinotecan—colon cancer	0.000276	0.00154	CcSEcCtD
Etoricoxib—Pancreatitis—Methotrexate—colon cancer	0.000275	0.00154	CcSEcCtD
Etoricoxib—Pain—Irinotecan—colon cancer	0.000274	0.00153	CcSEcCtD
Etoricoxib—Constipation—Irinotecan—colon cancer	0.000274	0.00153	CcSEcCtD
Etoricoxib—Angiopathy—Capecitabine—colon cancer	0.000274	0.00153	CcSEcCtD
Etoricoxib—Dyspnoea—Fluorouracil—colon cancer	0.000273	0.00153	CcSEcCtD
Etoricoxib—Somnolence—Fluorouracil—colon cancer	0.000272	0.00152	CcSEcCtD
Etoricoxib—Immune system disorder—Capecitabine—colon cancer	0.000272	0.00152	CcSEcCtD
Etoricoxib—Mediastinal disorder—Capecitabine—colon cancer	0.000272	0.00152	CcSEcCtD
Etoricoxib—Dyspepsia—Fluorouracil—colon cancer	0.00027	0.00151	CcSEcCtD
Etoricoxib—Arrhythmia—Capecitabine—colon cancer	0.000269	0.00151	CcSEcCtD
Etoricoxib—Abdominal discomfort—Methotrexate—colon cancer	0.000269	0.0015	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Vincristine—colon cancer	0.000269	0.0015	CcSEcCtD
Etoricoxib—Decreased appetite—Fluorouracil—colon cancer	0.000266	0.00149	CcSEcCtD
Etoricoxib—Alopecia—Capecitabine—colon cancer	0.000266	0.00149	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000265	0.00148	CcSEcCtD
Etoricoxib—Mental disorder—Capecitabine—colon cancer	0.000264	0.00148	CcSEcCtD
Etoricoxib—Feeling abnormal—Irinotecan—colon cancer	0.000264	0.00147	CcSEcCtD
Etoricoxib—Malnutrition—Capecitabine—colon cancer	0.000262	0.00147	CcSEcCtD
Etoricoxib—Erythema—Capecitabine—colon cancer	0.000262	0.00147	CcSEcCtD
Etoricoxib—Pain—Fluorouracil—colon cancer	0.000262	0.00147	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Irinotecan—colon cancer	0.000262	0.00146	CcSEcCtD
Etoricoxib—Upper respiratory tract infection—Methotrexate—colon cancer	0.000261	0.00146	CcSEcCtD
Etoricoxib—Abdominal pain—Vincristine—colon cancer	0.00026	0.00145	CcSEcCtD
Etoricoxib—Flatulence—Capecitabine—colon cancer	0.000259	0.00145	CcSEcCtD
Etoricoxib—Dysgeusia—Capecitabine—colon cancer	0.000257	0.00144	CcSEcCtD
Etoricoxib—Photosensitivity reaction—Methotrexate—colon cancer	0.000256	0.00143	CcSEcCtD
Etoricoxib—Abdominal pain—Irinotecan—colon cancer	0.000253	0.00141	CcSEcCtD
Etoricoxib—Feeling abnormal—Fluorouracil—colon cancer	0.000253	0.00141	CcSEcCtD
Etoricoxib—Muscle spasms—Capecitabine—colon cancer	0.000252	0.00141	CcSEcCtD
Etoricoxib—Pneumonia—Methotrexate—colon cancer	0.000251	0.00141	CcSEcCtD
Etoricoxib—Infestation NOS—Methotrexate—colon cancer	0.00025	0.0014	CcSEcCtD
Etoricoxib—Infestation—Methotrexate—colon cancer	0.00025	0.0014	CcSEcCtD
Etoricoxib—Stevens-Johnson syndrome—Methotrexate—colon cancer	0.000248	0.00139	CcSEcCtD
Etoricoxib—Vision blurred—Capecitabine—colon cancer	0.000247	0.00138	CcSEcCtD
Etoricoxib—Tremor—Capecitabine—colon cancer	0.000246	0.00138	CcSEcCtD
Etoricoxib—Renal failure—Methotrexate—colon cancer	0.000246	0.00137	CcSEcCtD
Etoricoxib—Stomatitis—Methotrexate—colon cancer	0.000244	0.00136	CcSEcCtD
Etoricoxib—Urticaria—Fluorouracil—colon cancer	0.000244	0.00136	CcSEcCtD
Etoricoxib—Conjunctivitis—Methotrexate—colon cancer	0.000243	0.00136	CcSEcCtD
Etoricoxib—Anaemia—Capecitabine—colon cancer	0.000243	0.00136	CcSEcCtD
Etoricoxib—Hypersensitivity—Vincristine—colon cancer	0.000242	0.00135	CcSEcCtD
Etoricoxib—Haematuria—Methotrexate—colon cancer	0.000238	0.00133	CcSEcCtD
Etoricoxib—Hepatobiliary disease—Methotrexate—colon cancer	0.000236	0.00132	CcSEcCtD
Etoricoxib—Epistaxis—Methotrexate—colon cancer	0.000236	0.00132	CcSEcCtD
Etoricoxib—Hypersensitivity—Irinotecan—colon cancer	0.000236	0.00132	CcSEcCtD
Etoricoxib—Asthenia—Vincristine—colon cancer	0.000236	0.00132	CcSEcCtD
Etoricoxib—Palpitations—Capecitabine—colon cancer	0.000232	0.0013	CcSEcCtD
Etoricoxib—Asthenia—Irinotecan—colon cancer	0.00023	0.00128	CcSEcCtD
Etoricoxib—Cough—Capecitabine—colon cancer	0.000229	0.00128	CcSEcCtD
Etoricoxib—Hypertension—Capecitabine—colon cancer	0.000227	0.00127	CcSEcCtD
Etoricoxib—Hypersensitivity—Fluorouracil—colon cancer	0.000226	0.00126	CcSEcCtD
Etoricoxib—Haemoglobin—Methotrexate—colon cancer	0.000226	0.00126	CcSEcCtD
Etoricoxib—Diarrhoea—Vincristine—colon cancer	0.000225	0.00126	CcSEcCtD
Etoricoxib—Hepatitis—Methotrexate—colon cancer	0.000224	0.00126	CcSEcCtD
Etoricoxib—Haemorrhage—Methotrexate—colon cancer	0.000224	0.00126	CcSEcCtD
Etoricoxib—Arthralgia—Capecitabine—colon cancer	0.000223	0.00125	CcSEcCtD
Etoricoxib—Chest pain—Capecitabine—colon cancer	0.000223	0.00125	CcSEcCtD
Etoricoxib—Pharyngitis—Methotrexate—colon cancer	0.000223	0.00125	CcSEcCtD
Etoricoxib—Anxiety—Capecitabine—colon cancer	0.000223	0.00125	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000222	0.00124	CcSEcCtD
Etoricoxib—Urinary tract disorder—Methotrexate—colon cancer	0.000222	0.00124	CcSEcCtD
Etoricoxib—Urethral disorder—Methotrexate—colon cancer	0.00022	0.00123	CcSEcCtD
Etoricoxib—Diarrhoea—Irinotecan—colon cancer	0.000219	0.00122	CcSEcCtD
Etoricoxib—Dry mouth—Capecitabine—colon cancer	0.000219	0.00122	CcSEcCtD
Etoricoxib—Dizziness—Vincristine—colon cancer	0.000217	0.00122	CcSEcCtD
Etoricoxib—Pruritus—Fluorouracil—colon cancer	0.000217	0.00121	CcSEcCtD
Etoricoxib—Visual impairment—Methotrexate—colon cancer	0.000216	0.00121	CcSEcCtD
Etoricoxib—Confusional state—Capecitabine—colon cancer	0.000216	0.00121	CcSEcCtD
Etoricoxib—Oedema—Capecitabine—colon cancer	0.000214	0.0012	CcSEcCtD
Etoricoxib—Infection—Capecitabine—colon cancer	0.000213	0.00119	CcSEcCtD
Etoricoxib—Erythema multiforme—Methotrexate—colon cancer	0.000212	0.00119	CcSEcCtD
Etoricoxib—Dizziness—Irinotecan—colon cancer	0.000212	0.00118	CcSEcCtD
Etoricoxib—Shock—Capecitabine—colon cancer	0.000211	0.00118	CcSEcCtD
Etoricoxib—Nervous system disorder—Capecitabine—colon cancer	0.00021	0.00117	CcSEcCtD
Etoricoxib—Eye disorder—Methotrexate—colon cancer	0.00021	0.00117	CcSEcCtD
Etoricoxib—Diarrhoea—Fluorouracil—colon cancer	0.00021	0.00117	CcSEcCtD
Etoricoxib—Thrombocytopenia—Capecitabine—colon cancer	0.00021	0.00117	CcSEcCtD
Etoricoxib—Tinnitus—Methotrexate—colon cancer	0.000209	0.00117	CcSEcCtD
Etoricoxib—Vomiting—Vincristine—colon cancer	0.000209	0.00117	CcSEcCtD
Etoricoxib—Cardiac disorder—Methotrexate—colon cancer	0.000208	0.00116	CcSEcCtD
Etoricoxib—Skin disorder—Capecitabine—colon cancer	0.000208	0.00116	CcSEcCtD
Etoricoxib—Rash—Vincristine—colon cancer	0.000207	0.00116	CcSEcCtD
Etoricoxib—Dermatitis—Vincristine—colon cancer	0.000207	0.00116	CcSEcCtD
Etoricoxib—Headache—Vincristine—colon cancer	0.000206	0.00115	CcSEcCtD
Etoricoxib—Anorexia—Capecitabine—colon cancer	0.000204	0.00114	CcSEcCtD
Etoricoxib—Angiopathy—Methotrexate—colon cancer	0.000204	0.00114	CcSEcCtD
Etoricoxib—Vomiting—Irinotecan—colon cancer	0.000203	0.00114	CcSEcCtD
Etoricoxib—Immune system disorder—Methotrexate—colon cancer	0.000203	0.00113	CcSEcCtD
Etoricoxib—Dizziness—Fluorouracil—colon cancer	0.000203	0.00113	CcSEcCtD
Etoricoxib—Mediastinal disorder—Methotrexate—colon cancer	0.000202	0.00113	CcSEcCtD
Etoricoxib—Rash—Irinotecan—colon cancer	0.000202	0.00113	CcSEcCtD
Etoricoxib—Dermatitis—Irinotecan—colon cancer	0.000202	0.00113	CcSEcCtD
Etoricoxib—Headache—Irinotecan—colon cancer	0.0002	0.00112	CcSEcCtD
Etoricoxib—Alopecia—Methotrexate—colon cancer	0.000198	0.00111	CcSEcCtD
Etoricoxib—Mental disorder—Methotrexate—colon cancer	0.000197	0.0011	CcSEcCtD
Etoricoxib—Malnutrition—Methotrexate—colon cancer	0.000195	0.00109	CcSEcCtD
Etoricoxib—Erythema—Methotrexate—colon cancer	0.000195	0.00109	CcSEcCtD
Etoricoxib—Nausea—Vincristine—colon cancer	0.000195	0.00109	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000195	0.00109	CcSEcCtD
Etoricoxib—Vomiting—Fluorouracil—colon cancer	0.000195	0.00109	CcSEcCtD
Etoricoxib—Insomnia—Capecitabine—colon cancer	0.000194	0.00108	CcSEcCtD
Etoricoxib—Rash—Fluorouracil—colon cancer	0.000193	0.00108	CcSEcCtD
Etoricoxib—Dermatitis—Fluorouracil—colon cancer	0.000193	0.00108	CcSEcCtD
Etoricoxib—Headache—Fluorouracil—colon cancer	0.000192	0.00107	CcSEcCtD
Etoricoxib—Dysgeusia—Methotrexate—colon cancer	0.000191	0.00107	CcSEcCtD
Etoricoxib—Dyspnoea—Capecitabine—colon cancer	0.000191	0.00107	CcSEcCtD
Etoricoxib—Nausea—Irinotecan—colon cancer	0.00019	0.00106	CcSEcCtD
Etoricoxib—Dyspepsia—Capecitabine—colon cancer	0.000189	0.00105	CcSEcCtD
Etoricoxib—Decreased appetite—Capecitabine—colon cancer	0.000186	0.00104	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Capecitabine—colon cancer	0.000185	0.00103	CcSEcCtD
Etoricoxib—Fatigue—Capecitabine—colon cancer	0.000185	0.00103	CcSEcCtD
Etoricoxib—Vision blurred—Methotrexate—colon cancer	0.000184	0.00103	CcSEcCtD
Etoricoxib—Constipation—Capecitabine—colon cancer	0.000183	0.00102	CcSEcCtD
Etoricoxib—Pain—Capecitabine—colon cancer	0.000183	0.00102	CcSEcCtD
Etoricoxib—Nausea—Fluorouracil—colon cancer	0.000182	0.00102	CcSEcCtD
Etoricoxib—Anaemia—Methotrexate—colon cancer	0.000181	0.00101	CcSEcCtD
Etoricoxib—Feeling abnormal—Capecitabine—colon cancer	0.000177	0.000987	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Capecitabine—colon cancer	0.000175	0.00098	CcSEcCtD
Etoricoxib—Cough—Methotrexate—colon cancer	0.00017	0.000953	CcSEcCtD
Etoricoxib—Urticaria—Capecitabine—colon cancer	0.00017	0.000952	CcSEcCtD
Etoricoxib—Abdominal pain—Capecitabine—colon cancer	0.000169	0.000947	CcSEcCtD
Etoricoxib—Arthralgia—Methotrexate—colon cancer	0.000166	0.00093	CcSEcCtD
Etoricoxib—Chest pain—Methotrexate—colon cancer	0.000166	0.00093	CcSEcCtD
Etoricoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000165	0.000924	CcSEcCtD
Etoricoxib—Confusional state—Methotrexate—colon cancer	0.000161	0.000899	CcSEcCtD
Etoricoxib—Anaphylactic shock—Methotrexate—colon cancer	0.000159	0.000892	CcSEcCtD
Etoricoxib—Infection—Methotrexate—colon cancer	0.000158	0.000886	CcSEcCtD
Etoricoxib—Hypersensitivity—Capecitabine—colon cancer	0.000158	0.000883	CcSEcCtD
Etoricoxib—Nervous system disorder—Methotrexate—colon cancer	0.000156	0.000874	CcSEcCtD
Etoricoxib—Thrombocytopenia—Methotrexate—colon cancer	0.000156	0.000873	CcSEcCtD
Etoricoxib—Skin disorder—Methotrexate—colon cancer	0.000155	0.000866	CcSEcCtD
Etoricoxib—Asthenia—Capecitabine—colon cancer	0.000154	0.000859	CcSEcCtD
Etoricoxib—Anorexia—Methotrexate—colon cancer	0.000152	0.00085	CcSEcCtD
Etoricoxib—Pruritus—Capecitabine—colon cancer	0.000152	0.000847	CcSEcCtD
Etoricoxib—Diarrhoea—Capecitabine—colon cancer	0.000147	0.00082	CcSEcCtD
Etoricoxib—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000145	0.000812	CcSEcCtD
Etoricoxib—Insomnia—Methotrexate—colon cancer	0.000144	0.000807	CcSEcCtD
Etoricoxib—Dyspnoea—Methotrexate—colon cancer	0.000142	0.000795	CcSEcCtD
Etoricoxib—Somnolence—Methotrexate—colon cancer	0.000142	0.000793	CcSEcCtD
Etoricoxib—Dizziness—Capecitabine—colon cancer	0.000142	0.000792	CcSEcCtD
Etoricoxib—Dyspepsia—Methotrexate—colon cancer	0.00014	0.000785	CcSEcCtD
Etoricoxib—Decreased appetite—Methotrexate—colon cancer	0.000139	0.000775	CcSEcCtD
Etoricoxib—Gastrointestinal disorder—Methotrexate—colon cancer	0.000138	0.00077	CcSEcCtD
Etoricoxib—Fatigue—Methotrexate—colon cancer	0.000137	0.000769	CcSEcCtD
Etoricoxib—Pain—Methotrexate—colon cancer	0.000136	0.000763	CcSEcCtD
Etoricoxib—Vomiting—Capecitabine—colon cancer	0.000136	0.000762	CcSEcCtD
Etoricoxib—Rash—Capecitabine—colon cancer	0.000135	0.000755	CcSEcCtD
Etoricoxib—Dermatitis—Capecitabine—colon cancer	0.000135	0.000755	CcSEcCtD
Etoricoxib—Headache—Capecitabine—colon cancer	0.000134	0.00075	CcSEcCtD
Etoricoxib—Feeling abnormal—Methotrexate—colon cancer	0.000131	0.000735	CcSEcCtD
Etoricoxib—Gastrointestinal pain—Methotrexate—colon cancer	0.00013	0.000729	CcSEcCtD
Etoricoxib—Nausea—Capecitabine—colon cancer	0.000127	0.000712	CcSEcCtD
Etoricoxib—Urticaria—Methotrexate—colon cancer	0.000127	0.000708	CcSEcCtD
Etoricoxib—Abdominal pain—Methotrexate—colon cancer	0.000126	0.000705	CcSEcCtD
Etoricoxib—Hypersensitivity—Methotrexate—colon cancer	0.000117	0.000657	CcSEcCtD
Etoricoxib—Asthenia—Methotrexate—colon cancer	0.000114	0.00064	CcSEcCtD
Etoricoxib—Pruritus—Methotrexate—colon cancer	0.000113	0.000631	CcSEcCtD
Etoricoxib—Diarrhoea—Methotrexate—colon cancer	0.000109	0.00061	CcSEcCtD
Etoricoxib—Dizziness—Methotrexate—colon cancer	0.000105	0.00059	CcSEcCtD
Etoricoxib—Vomiting—Methotrexate—colon cancer	0.000101	0.000567	CcSEcCtD
Etoricoxib—Rash—Methotrexate—colon cancer	0.000101	0.000562	CcSEcCtD
Etoricoxib—Dermatitis—Methotrexate—colon cancer	0.0001	0.000562	CcSEcCtD
Etoricoxib—Headache—Methotrexate—colon cancer	9.99e-05	0.000559	CcSEcCtD
Etoricoxib—Nausea—Methotrexate—colon cancer	9.47e-05	0.00053	CcSEcCtD
Etoricoxib—PTGS2—Metabolism—ODC1—colon cancer	9.01e-05	0.000796	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—CHST5—colon cancer	9.01e-05	0.000796	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—MYC—colon cancer	8.97e-05	0.000793	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—colon cancer	8.95e-05	0.000791	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	8.87e-05	0.000784	CbGpPWpGaD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—EGFR—colon cancer	8.87e-05	0.000784	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—MYC—colon cancer	8.81e-05	0.000778	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—TGFB1—colon cancer	8.79e-05	0.000777	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—colon cancer	8.78e-05	0.000776	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—colon cancer	8.78e-05	0.000776	CbGpPWpGaD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—TP53—colon cancer	8.77e-05	0.000775	CbGpPWpGaD
Etoricoxib—MAPK14—VEGFA-VEGFR2 Pathway—AKT1—colon cancer	8.76e-05	0.000775	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—PIK3CA—colon cancer	8.7e-05	0.000769	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	8.64e-05	0.000764	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—EGFR—colon cancer	8.61e-05	0.000761	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ODC1—colon cancer	8.48e-05	0.00075	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—CHST5—colon cancer	8.48e-05	0.00075	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AXIN2—colon cancer	8.47e-05	0.000749	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—BCL10—colon cancer	8.44e-05	0.000746	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CA7—colon cancer	8.41e-05	0.000744	CbGpPWpGaD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—KRAS—colon cancer	8.38e-05	0.000741	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—SRC—colon cancer	8.35e-05	0.000738	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—colon cancer	8.29e-05	0.000733	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by VEGF—AKT1—colon cancer	8.27e-05	0.000731	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—KRAS—colon cancer	8.14e-05	0.000719	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—NRAS—colon cancer	8.03e-05	0.00071	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	7.95e-05	0.000703	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	7.93e-05	0.000701	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—SRC—colon cancer	7.89e-05	0.000698	CbGpPWpGaD
Etoricoxib—MAPK14—BDNF signaling pathway—HRAS—colon cancer	7.83e-05	0.000692	CbGpPWpGaD
Etoricoxib—MAPK14—Insulin Signaling—PIK3CA—colon cancer	7.77e-05	0.000687	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	7.77e-05	0.000687	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—AXIN2—colon cancer	7.73e-05	0.000683	CbGpPWpGaD
Etoricoxib—PTGS2—C-MYB transcription factor network—HRAS—colon cancer	7.69e-05	0.00068	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—VEGFA—colon cancer	7.69e-05	0.000679	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—HNF4A—colon cancer	7.68e-05	0.000679	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—MYC—colon cancer	7.46e-05	0.00066	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—TGFB1—colon cancer	7.45e-05	0.000658	CbGpPWpGaD
Etoricoxib—MAPK14—TGF-beta Signaling Pathway—AKT1—colon cancer	7.41e-05	0.000655	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—CDKN1A—colon cancer	7.4e-05	0.000654	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—CASP3—colon cancer	7.37e-05	0.000651	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	7.34e-05	0.000649	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—EGFR—colon cancer	7.32e-05	0.000647	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—EGFR—colon cancer	7.3e-05	0.000645	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—TP53—colon cancer	7.23e-05	0.000639	CbGpPWpGaD
Etoricoxib—MAPK14—Insulin Signaling—HRAS—colon cancer	7.19e-05	0.000636	CbGpPWpGaD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—HRAS—colon cancer	7.12e-05	0.000629	CbGpPWpGaD
Etoricoxib—MAPK14—Regulation of toll-like receptor signaling pathway—AKT1—colon cancer	7.11e-05	0.000628	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—TGFB1—colon cancer	7.06e-05	0.000624	CbGpPWpGaD
Etoricoxib—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—colon cancer	7.05e-05	0.000623	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—EP300—colon cancer	7.04e-05	0.000622	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—CDKN1A—colon cancer	6.94e-05	0.000613	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—KRAS—colon cancer	6.91e-05	0.000611	CbGpPWpGaD
Etoricoxib—MAPK14—BDNF signaling pathway—AKT1—colon cancer	6.91e-05	0.000611	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—BCL2L1—colon cancer	6.8e-05	0.000601	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	6.75e-05	0.000596	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—VEGFA—colon cancer	6.67e-05	0.000589	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular Senescence—TP53—colon cancer	6.67e-05	0.000589	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ODC1—colon cancer	6.54e-05	0.000578	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—CHST5—colon cancer	6.54e-05	0.000578	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	6.53e-05	0.000577	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—PPARG—colon cancer	6.52e-05	0.000576	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	6.5e-05	0.000575	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—FGFR3—colon cancer	6.5e-05	0.000574	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CA7—colon cancer	6.49e-05	0.000574	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—SRC—colon cancer	6.42e-05	0.000568	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—PIK3CA—colon cancer	6.35e-05	0.000561	CbGpPWpGaD
Etoricoxib—MAPK14—Insulin Signaling—AKT1—colon cancer	6.35e-05	0.000561	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	6.33e-05	0.00056	CbGpPWpGaD
Etoricoxib—MAPK14—EGF/EGFR Signaling Pathway—AKT1—colon cancer	6.29e-05	0.000556	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	6.27e-05	0.000554	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—NRAS—colon cancer	6.18e-05	0.000546	CbGpPWpGaD
Etoricoxib—PTGS2—Spinal Cord Injury—TP53—colon cancer	6.13e-05	0.000542	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	6.12e-05	0.000541	CbGpPWpGaD
Etoricoxib—MAPK14—MAPK Signaling Pathway—AKT1—colon cancer	6.11e-05	0.00054	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—CHST5—colon cancer	6.02e-05	0.000532	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ODC1—colon cancer	6.02e-05	0.000532	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	6e-05	0.000531	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—CHST5—colon cancer	5.97e-05	0.000527	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ODC1—colon cancer	5.97e-05	0.000527	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—HRAS—colon cancer	5.88e-05	0.000519	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	5.83e-05	0.000515	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	5.67e-05	0.000501	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—EGFR—colon cancer	5.63e-05	0.000497	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	5.52e-05	0.000488	CbGpPWpGaD
Etoricoxib—MAPK14—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	5.51e-05	0.000487	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—KRAS—colon cancer	5.32e-05	0.00047	CbGpPWpGaD
Etoricoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—AKT1—colon cancer	5.19e-05	0.000459	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—CHST5—colon cancer	5.1e-05	0.000451	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ODC1—colon cancer	5.1e-05	0.000451	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	5.08e-05	0.000449	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	5.07e-05	0.000448	CbGpPWpGaD
Etoricoxib—MAPK14—Cellular responses to stress—TP53—colon cancer	5.04e-05	0.000445	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	4.97e-05	0.000439	CbGpPWpGaD
Etoricoxib—MAPK14—Metabolism of mRNA—AKT1—colon cancer	4.94e-05	0.000437	CbGpPWpGaD
Etoricoxib—MAPK14—Platelet activation, signaling and aggregation—AKT1—colon cancer	4.9e-05	0.000434	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—PIK3CA—colon cancer	4.89e-05	0.000432	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	4.69e-05	0.000415	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CD8A—colon cancer	4.63e-05	0.000409	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—CTNNB1—colon cancer	4.59e-05	0.000406	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—HRAS—colon cancer	4.52e-05	0.000399	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	4.31e-05	0.000381	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—EP300—colon cancer	4.26e-05	0.000377	CbGpPWpGaD
Etoricoxib—MAPK14—Metabolism of RNA—AKT1—colon cancer	4.23e-05	0.000374	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—EP300—colon cancer	4.18e-05	0.00037	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	4.17e-05	0.000369	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—SRC—colon cancer	4.15e-05	0.000367	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—SRC—colon cancer	4.07e-05	0.00036	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—CTNNB1—colon cancer	4.05e-05	0.000358	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—VEGFA—colon cancer	4.04e-05	0.000357	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling by NGF—AKT1—colon cancer	3.99e-05	0.000353	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—NRAS—colon cancer	3.99e-05	0.000353	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—VEGFA—colon cancer	3.96e-05	0.00035	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—CDKN1A—colon cancer	3.96e-05	0.00035	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—BCL2L1—colon cancer	3.96e-05	0.00035	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—CHST5—colon cancer	3.93e-05	0.000348	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ODC1—colon cancer	3.93e-05	0.000348	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—NRAS—colon cancer	3.91e-05	0.000346	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—FGFR3—colon cancer	3.78e-05	0.000334	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—EP300—colon cancer	3.77e-05	0.000333	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	3.72e-05	0.000329	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—TGFB1—colon cancer	3.71e-05	0.000328	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—SRC—colon cancer	3.66e-05	0.000324	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—TGFB1—colon cancer	3.64e-05	0.000321	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—EGFR—colon cancer	3.64e-05	0.000321	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—NRAS—colon cancer	3.52e-05	0.000311	CbGpPWpGaD
Etoricoxib—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	3.52e-05	0.000311	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—KRAS—colon cancer	3.43e-05	0.000304	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—KRAS—colon cancer	3.37e-05	0.000298	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—PPARG—colon cancer	3.33e-05	0.000295	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—EGFR—colon cancer	3.21e-05	0.000284	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CDH1—colon cancer	3.2e-05	0.000283	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—PIK3CA—colon cancer	3.09e-05	0.000274	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—KRAS—colon cancer	3.03e-05	0.000268	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—TP53—colon cancer	2.99e-05	0.000265	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—HRAS—colon cancer	2.92e-05	0.000258	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—HRAS—colon cancer	2.86e-05	0.000253	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—PIK3CA—colon cancer	2.79e-05	0.000246	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.7e-05	0.000239	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—HRAS—colon cancer	2.58e-05	0.000228	CbGpPWpGaD
Etoricoxib—MAPK14—Developmental Biology—AKT1—colon cancer	2.58e-05	0.000228	CbGpPWpGaD
Etoricoxib—MAPK14—Hemostasis—AKT1—colon cancer	2.53e-05	0.000223	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.46e-05	0.000218	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—FGFR3—colon cancer	2.45e-05	0.000216	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—EP300—colon cancer	2.43e-05	0.000215	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—ABCB1—colon cancer	2.38e-05	0.00021	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CTNNB1—colon cancer	2.36e-05	0.000209	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—TYMS—colon cancer	2.34e-05	0.000207	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—CDKN1A—colon cancer	2.31e-05	0.000204	CbGpPWpGaD
Etoricoxib—MAPK14—Innate Immune System—AKT1—colon cancer	2.28e-05	0.000201	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—APC—colon cancer	2.25e-05	0.000199	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—ABCB1—colon cancer	2.24e-05	0.000198	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—FGFR3—colon cancer	2.23e-05	0.000197	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—TYMS—colon cancer	2.2e-05	0.000195	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—EP300—colon cancer	2.19e-05	0.000194	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—SRC—colon cancer	2.13e-05	0.000189	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	2.12e-05	0.000188	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—BRAF—colon cancer	2.11e-05	0.000187	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—colon cancer	2.1e-05	0.000186	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—NRAS—colon cancer	2.05e-05	0.000181	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—APC—colon cancer	2.05e-05	0.000181	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.94e-05	0.000171	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—BRAF—colon cancer	1.93e-05	0.00017	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—MYC—colon cancer	1.9e-05	0.000168	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—EGFR—colon cancer	1.87e-05	0.000165	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.8e-05	0.000159	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.77e-05	0.000156	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—KRAS—colon cancer	1.77e-05	0.000156	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—ABCB1—colon cancer	1.73e-05	0.000153	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—TYMS—colon cancer	1.7e-05	0.00015	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PPARG—colon cancer	1.66e-05	0.000146	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	1.66e-05	0.000146	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—PIK3CA—colon cancer	1.62e-05	0.000143	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.61e-05	0.000142	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—ABCB1—colon cancer	1.59e-05	0.000141	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CASP3—colon cancer	1.58e-05	0.00014	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—ABCB1—colon cancer	1.58e-05	0.000139	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—TYMS—colon cancer	1.56e-05	0.000138	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PPARG—colon cancer	1.56e-05	0.000138	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—TYMS—colon cancer	1.55e-05	0.000137	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CCND1—colon cancer	1.54e-05	0.000136	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CTNNB1—colon cancer	1.53e-05	0.000135	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—HRAS—colon cancer	1.5e-05	0.000133	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—CDKN1A—colon cancer	1.49e-05	0.000132	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—EP300—colon cancer	1.42e-05	0.000125	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CTNNB1—colon cancer	1.39e-05	0.000123	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—SRC—colon cancer	1.38e-05	0.000122	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—colon cancer	1.38e-05	0.000122	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—CDKN1A—colon cancer	1.36e-05	0.00012	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—ABCB1—colon cancer	1.35e-05	0.000119	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—VEGFA—colon cancer	1.34e-05	0.000119	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—NRAS—colon cancer	1.33e-05	0.000117	CbGpPWpGaD
Etoricoxib—MAPK14—Immune System—AKT1—colon cancer	1.33e-05	0.000117	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—TYMS—colon cancer	1.32e-05	0.000117	CbGpPWpGaD
Etoricoxib—MAPK14—Gene Expression—AKT1—colon cancer	1.32e-05	0.000117	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.31e-05	0.000116	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—EP300—colon cancer	1.29e-05	0.000114	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—SRC—colon cancer	1.26e-05	0.000111	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—MYC—colon cancer	1.24e-05	0.000109	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TGFB1—colon cancer	1.23e-05	0.000109	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PTGS2—colon cancer	1.23e-05	0.000108	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—NRAS—colon cancer	1.21e-05	0.000107	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—EGFR—colon cancer	1.21e-05	0.000107	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PPARG—colon cancer	1.2e-05	0.000106	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.19e-05	0.000105	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—KRAS—colon cancer	1.14e-05	0.000101	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—MYC—colon cancer	1.13e-05	9.97e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—TGFB1—colon cancer	1.12e-05	9.94e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PPARG—colon cancer	1.11e-05	9.78e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—EGFR—colon cancer	1.1e-05	9.75e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PPARG—colon cancer	1.1e-05	9.69e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—EP300—colon cancer	1.08e-05	9.58e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—PIK3CA—colon cancer	1.05e-05	9.27e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—KRAS—colon cancer	1.04e-05	9.21e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—ABCB1—colon cancer	1.04e-05	9.19e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—TYMS—colon cancer	1.02e-05	9.03e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—EP300—colon cancer	1.02e-05	9.02e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	1.02e-05	9e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—TP53—colon cancer	1.02e-05	8.97e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—HRAS—colon cancer	9.71e-06	8.58e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—PIK3CA—colon cancer	9.57e-06	8.46e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PTGS2—colon cancer	9.46e-06	8.36e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PPARG—colon cancer	9.37e-06	8.28e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—HRAS—colon cancer	8.86e-06	7.83e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PTGS2—colon cancer	8.7e-06	7.69e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PTGS2—colon cancer	8.63e-06	7.63e-05	CbGpPWpGaD
Etoricoxib—MAPK14—Signaling Pathways—AKT1—colon cancer	8.57e-06	7.58e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—PIK3CA—colon cancer	8.02e-06	7.09e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—EP300—colon cancer	7.87e-06	6.96e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Disease—AKT1—colon cancer	7.82e-06	6.91e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—PIK3CA—colon cancer	7.55e-06	6.67e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PTGS2—colon cancer	7.37e-06	6.52e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—EP300—colon cancer	7.24e-06	6.4e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PPARG—colon cancer	7.23e-06	6.39e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—EP300—colon cancer	7.18e-06	6.34e-05	CbGpPWpGaD
Etoricoxib—PTGS2—Metabolism—AKT1—colon cancer	6.55e-06	5.79e-05	CbGpPWpGaD
Etoricoxib—CYP2E1—Metabolism—AKT1—colon cancer	6.16e-06	5.45e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—EP300—colon cancer	6.13e-06	5.42e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—PIK3CA—colon cancer	5.82e-06	5.15e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PTGS2—colon cancer	5.69e-06	5.03e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—PIK3CA—colon cancer	5.35e-06	4.73e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—PIK3CA—colon cancer	5.31e-06	4.69e-05	CbGpPWpGaD
Etoricoxib—CYP2C19—Metabolism—AKT1—colon cancer	4.76e-06	4.2e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—EP300—colon cancer	4.73e-06	4.18e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—PIK3CA—colon cancer	4.54e-06	4.01e-05	CbGpPWpGaD
Etoricoxib—CYP2D6—Metabolism—AKT1—colon cancer	4.37e-06	3.87e-05	CbGpPWpGaD
Etoricoxib—CYP2C9—Metabolism—AKT1—colon cancer	4.34e-06	3.83e-05	CbGpPWpGaD
Etoricoxib—CYP1A2—Metabolism—AKT1—colon cancer	3.71e-06	3.28e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—PIK3CA—colon cancer	3.5e-06	3.09e-05	CbGpPWpGaD
Etoricoxib—CYP3A4—Metabolism—AKT1—colon cancer	2.86e-06	2.53e-05	CbGpPWpGaD
